Brief Title
Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy
Official Title
Open-Label, Phase Ⅱ Study of Anlotinib Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of no Less Than Second-line Chemotherapy or Targeted Therapy
Brief Summary
The purpose of this single arm, phase Ⅱ clinical trial is to evaluate the efficacy and safety of Anlotinib Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma after failure of no less than second-line chemotherapy or targeted therapy
Study Phase
Phase 2
Study Type
Interventional
Primary Outcome
disease control rate
Condition
Nasopharyngeal Carcinoma
Intervention
Anlotinib
Study Arms / Comparison Groups
Anlotinib
Description:
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Estimated Enrollment
39
Start Date
April 29, 2019
Completion Date
April 29, 2026
Primary Completion Date
April 29, 2021
Eligibility Criteria
Inclusion Criteria: - biopsy proved nasopharyngeal carcinoma; - stage IVB according to American Joint Committee on Cancer(AJCC) edition VIII, or recurrent disease after chemotherapy and/or radiotherapy; - 18 years or older; without other malignancy; - proper functioning of the major organs. Exclusion Criteria: - allergic to anlotinib; - female within gestation period or lactation; - patients received drug of other clinical trial within 4 weeks.
Gender
All
Ages
18 Years - 70 Years
Accepts Healthy Volunteers
No
Contacts
, 0086-20-87342823, [email protected]
Location Countries
China
Location Countries
China
Administrative Informations
NCT ID
NCT03906058
Organization ID
B2018-167
Responsible Party
Principal Investigator
Study Sponsor
Sun Yat-sen University
Study Sponsor
, ,
Verification Date
July 2019